Chemomab Therapeutics (CMMB) reshapes board and audit committee leadership

Rhea-AI Filing Summary

Chemomab Therapeutics Ltd. announced several changes to its board and board committees. On June 1, 2026, the board appointed Gwen Melincoff as an independent Class I director and chair of the nominating and governance committee, bringing the board size to five directors.

On May 29, 2026, directors Claude Nicaise and Jill Quigley resigned from the board and the audit committee, with the company stating their resignations were not due to any disagreements over operations, policies, or practices. The board then appointed Neil Cohen and Nissim Darvish to the audit committee, with Cohen as chair, and reorganized the nominating and governance committee to be chaired by Melincoff with Darvish as a member.

Key Figures

Board size: 5 directors Industry experience: Over 25 years Resignation date: May 29, 2026 +1 more

4 metrics

Board size 5 directors After June 1, 2026 appointment

Industry experience Over 25 years Gwen Melincoff biotechnology and pharma experience

Resignation date May 29, 2026 Resignations of Nicaise and Quigley

Appointment date June 1, 2026 Appointments of Melincoff, Cohen, Darvish

Key Terms

independent director, nominating and governance committee, Audit Committee, foreign private issuer, +1 more

5 terms

independent director financial

"The Board determined Ms. Melincoff to be an independent director."

An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.

nominating and governance committee financial

"as a member and chair of the nominating and governance committee of the Board"

A nominating and governance committee is a group of board members tasked with choosing and evaluating directors, planning leadership succession, and setting the company’s board-related rules and ethical standards. Think of it as the company’s hiring and rule-making panel for its top overseers. Its work matters to investors because it shapes who governs the company, how leadership transitions are handled, and whether the board can effectively oversee management and protect shareholder interests.

Audit Committee financial

"resigned from her position as a director and a member of the Audit Committee"

A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

Class I Director financial

"appointed Gwen Melincoff to the Board as a Class I Director"

A class I director is a member of a company’s board who belongs to one of several groups whose terms expire in a specified year under a staggered election system; each class is elected on a different cycle so only a portion of the board faces re-election each year. This matters to investors because it affects how quickly control of the board can change, the company’s continuity and oversight, and the ease of mounting or defending against takeover efforts—think of a team where only some players are replaced each season rather than the whole roster at once.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number 001-38807

CHEMOMAB THERAPEUTICS LTD.
(Translation of registrant’s name into English)

10 Habarzel Street, Building C, 10th Floor, Tel-Aviv, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

EXPLANATORY NOTE

On June 1, 2026, the Board of Directors (the “Board”) of Chemomab Therapeutics Ltd. (the “Company”) appointed Gwen Melincoff to the Board as a Class I Director and as a member and chair of the nominating and governance committee of the Board (the “Nominating Committee”), effective immediately. The Board determined Ms. Melincoff to be an independent director.

On May 29, 2026, Mr. Claude Nicaise resigned from his position as a director and a member of the audit committee of the Board (the “Audit Committee”), effective immediately. Simultaneously, Ms. Jill Quigley resigned from her position as a director and a member of the Audit Committee, effective immediately. Neither Mr. Nicaise’s nor Ms. Quigley’s resignation was the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.

On June 1, 2026, the Board appointed Mr. Neil Cohen and Dr. Nissim Darvish to the Audit Committee, effective immediately. Following the appointments of Mr. Cohen and Dr. Darvish to the Audit Committee, such committee will be comprised of Neil Cohen (Chair), Dr. Nissim Darvish and Dr. Alan Moses.

On June 1, 2026, Mr. Neil Cohen resigned from his position as a member and chair of the Nominating Committee, effective immediately. As a result of Ms. Melincoff’s appointment to the Nominating Committee, such committee is comprised of Gwen Melincoff (Chair) and Dr. Nissim Darvish.

With Ms. Melincoff’s appointment to the Board, the size of the Board will be five directors. The biographical information for Ms. Melincoff appears below:

Gwen Melincoff is a seasoned business development and venture professional with over 25 years of deal making and management experience in the biotechnology and pharmaceutical industries. Ms. Melincoff has been a member of the board of directors of Gain Therapeutics, Inc. since January 2021. Ms. Melincoff is currently managing director at Gemini Advisors LLC, a biopharmaceutical consultancy (since 2013). Ms. Melincoff serves on the board of directors of Protalix Biotherapeutics, Inc., and in an advisory capacity at a number of pharmaceutical companies. From August 2017 through May 2025, she served on the board of directors of Collegium Pharmaceutical, Inc., April 2017 through June 2024 on the board of directors of Soleno Therapeutics, Inc., January 2017 through December 2018 on the board of directors of Kamada Ltd., the board of directors of Photocure ASA from April 2017 through June 2020 and from June 2014 through November 2016 on the board of directors of Tobira Therapeutics Inc. (acquired by Allergan plc). From August 2014 through September 2016, Ms. Melincoff previously served as Vice President of Business Development at BTG International Inc., a UK-specialist healthcare company. Prior to BTG, Ms. Melincoff was Senior Vice President of Corporate Development at Shire Plc (acquired by Takeda). Additionally, she led the Shire Strategic Investment Group, the venture capital arm of Shire Plc. Ms. Melincoff was Vice President of Business Development at Adolor Corporation and held executive positions at Eastman Kodak for over ten years in a number of their health care companies. Ms. Melincoff holds a B.S. in Biology from The George Washington University and an M.S. in Management and Health Care Administration from Pennsylvania State University. Ms. Melincoff has also attained the designation of Certified Licensing Professional (CLP™). Ms. Melincoff was named to the “Top Women in Biotech 2013” by Fierce Biotech and to the Powerlist 100 of Corporate Venture Capital in 2012.

This Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (File No. 333-275002 and 333-281750) and Form S-8 (File No. 333-259489 and No. 333-266868).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CHEMOMAB THERAPEUTICS LTD.
Date: June 2, 2026	By:	/s/ Sigal Fattal
		Sigal Fattal
		Chief Financial Officer

FAQ

What board change did Chemomab Therapeutics (CMMB) announce in June 2026?

Chemomab Therapeutics appointed Gwen Melincoff as an independent Class I director and chair of its nominating and governance committee. This appointment, effective June 1, 2026, brings extensive biotechnology and pharmaceutical business development experience to the board.

Which Chemomab Therapeutics (CMMB) directors resigned in May 2026?

Claude Nicaise and Jill Quigley resigned as directors and audit committee members on May 29, 2026. The company stated their departures were not due to disagreements regarding Chemomab’s operations, policies, or practices, indicating routine governance changes rather than a dispute.

How did Chemomab Therapeutics (CMMB) change its audit committee composition?

Effective June 1, 2026, Chemomab appointed Neil Cohen and Nissim Darvish to its audit committee, with Cohen serving as chair alongside Darvish and Alan Moses. These appointments followed the resignations of former audit committee members Claude Nicaise and Jill Quigley.

What is the new structure of Chemomab Therapeutics’ (CMMB) nominating and governance committee?

After the June 1, 2026 changes, Chemomab’s nominating and governance committee is chaired by Gwen Melincoff, with Nissim Darvish as the other member. Neil Cohen resigned from his prior role as chair and member of this committee when the changes took effect.

How large is the Chemomab Therapeutics (CMMB) board after the June 2026 changes?

Following the appointment of Gwen Melincoff as an independent Class I director on June 1, 2026, Chemomab’s board consists of five directors. This size reflects the updated composition after the resignations and committee reassignments described in the same period.

What relevant experience does new Chemomab Therapeutics (CMMB) director Gwen Melincoff bring?

Gwen Melincoff brings over 25 years of deal-making and management experience in biotechnology and pharmaceuticals. She has served in senior business development roles at companies like Shire and BTG International and sits on multiple biopharmaceutical boards, complementing Chemomab’s governance capabilities.